Baseline E(2) levels are higher in BRCA2 mutation carriers: a potential target for prevention?

Area of Science:

• Oncology
• Genetics
• Endocrinology

Background:

• BRCA gene mutations are established breast cancer risk factors.
• Elevated serum estradiol (E2) is also a known risk factor for breast cancer.
• Understanding the interplay between BRCA mutations and E2 levels is crucial for risk assessment.

Purpose of the Study:

• To investigate the association between BRCA gene mutations and serum estradiol (E2) levels in women with breast cancer.
• To determine if specific BRCA mutations correlate with different E2 concentrations.

Main Methods:

• Serum E2 levels were measured in 96 women with breast cancer undergoing BRCA testing.
• Baseline E2 levels were assessed on menstrual cycle days 2-3.
• Statistical analyses compared E2 levels between BRCA mutation carriers (BRCA1/2) and non-carriers.

Main Results:

• Women with BRCA2 mutations exhibited significantly higher basal serum E2 levels compared to BRCA1 carriers and non-carriers (71.7 pg/ml vs. 45.5 pg/ml vs. 38.5 pg/ml, p=0.03).
• BRCA2 mutation carriers had a 3.1-fold increased risk of high basal E2 levels (>48 pg/ml) after adjusting for age and BMI.
• BRCA mutation carriers with high E2 levels were younger than those with low E2 levels (31.4 vs. 34.7 years, p=0.04).

Conclusions:

• A significant association was found between high basal serum E2 levels and BRCA2 mutations in this pilot study.
• Increased E2 production may contribute to the pathogenesis of BRCA2-mutation-related breast cancer.
• Further research is warranted to elucidate the role of E2 in BRCA2-associated tumorigenesis.